Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the initiation of Cohort 9 in its ongoing Phase I/IIa dose escalation trial of HDP-101, the Company’s lead ATAC candidate for the treatment of relapsed or refractory multiple myeloma.
– HDP-101 continues to demonstrate a favorable safety profile with no dose-limiting toxicities observed
– Early evidence of clinical activity observed in Cohort 8, highlighted by a very good partial response observed in one patient